Supernus Pharma (SUPN): Settlement Pushed Out Again - Jefferies

October 13, 2016 7:32 AM EDT
Get Alerts SUPN Hot Sheet
Price: $23.00 +3.14%

Rating Summary:
    6 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade SUPN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies analyst, David Steinberg, reiterated his Buy rating on shares of Supernus Pharmaceuticals (NASDAQ: SUPN) after the Judge delays settlement talks to a likely Q4 or early 2017.

Volume growth remains strong for the company’s two epilepsy brands and there are a bevy of regulatory and clinical catalysts on the horizon. Near term however, depends on resolving the TXR patent dispute. Despite recent delays in the legal process the analyst believes the most likely outcome is a settlement with generic challenger TEVA and if a settlement is to be reached, it would occur in the next 1-4 months.

No change to the price target of $28.

For an analyst ratings summary and ratings history on Supernus Pharmaceuticals click here. For more ratings news on Supernus Pharmaceuticals click here.

Shares of Supernus Pharmaceuticals closed at $21.54 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment